Start with what you want to achieve. Each use case links to the compounds with published research supporting that application â so you can read the science before drawing any conclusions.
Peptides that influence GLP-1, GIP and glucagon receptors drive significant fat loss while preserving lean muscle. Clinical trials show up to 24% body weight reduction.
Phase II/III clinical trials. FDA-approved compounds in this category.
Mitochondrial peptides restore cellular energy production that declines with age. AMPK activation, NAD+ optimisation and electron transport chain repair directly improve energy at the cellular level.
Published human trials. SS-31 FDA approved. MOTS-c Cell Metabolism 2015.
Russian clinical peptides with 30+ years of human data for focus, memory and neuroprotection. BDNF upregulation, dopamine modulation and synaptogenesis through distinct mechanisms.
30+ years Russian clinical use. Human trials in stroke recovery and cognitive impairment.
GABA-A modulation, delta wave induction and pineal restoration for comprehensive sleep quality improvement without sedation or dependence. Addresses the neurological root of poor sleep â cortisol dysregulation, anxiety and circadian disruption â in high-functioning individuals.
Selank approved in Russia for anxiety. DSIP human sleep studies since 1977. Epithalon restores melatonin in published human research.
BPC-157 has 36+ published studies for tendon and ligament healing without scar tissue formation. 87.5% positive response rate in knee pain studies. TB-500 provides systemic vascular support.
36+ published studies BPC-157. 87.5% knee pain response rate (human). Veterinary use TB-500.
GH axis optimisation accelerates recovery from training while tissue repair peptides address connective tissue integrity under increased load. The most commonly researched combination in athletic contexts.
CJC-1295 Phase II human trials. BPC-157 36+ studies. TB-500 veterinary approval.
GHK-Cu is the most extensively researched anti-aging peptide in dermatology â stimulating collagen synthesis, extending hair growth cycles and improving skin density. Comparable to minoxidil in some hair studies.
GHK-Cu cosmetic research 40+ years. Glutathione skin brightening human trials. Published hair growth data.
The most comprehensive anti-aging stack addresses aging at the genomic, cellular and mitochondrial levels simultaneously. A 266-person human cohort demonstrated 4.1x mortality reduction.
266-person human cohort Epithalon. SS-31 FDA approved. FOXO4-DRI Cell (2017).
Thymosin Alpha-1 is approved as Zadaxin in 37 countries for immune restoration. Restores CD8+ T-cell surveillance that suppresses HSV and VZV reactivation â critical for anyone on GH-stimulating protocols.
Thymalfasin Phase II/III human trials. Approved 37 countries. Published HSV reactivation data.
Triple receptor agonism of GIP, GLP-1 and glucagon receptors produces comprehensive metabolic improvement â blood sugar regulation, insulin sensitivity and visceral fat reduction backed by clinical trials.
Retatrutide Phase II FDA trial. Tesamorelin FDA approved. MOTS-c Cell Metabolism 2015.
GHK-Cu directly activates osteoblasts â the cells that build bone. Combined with TB-500 angiogenesis and BPC-157 healing, the GLOW stack addresses both bone matrix and vascular supply for comprehensive bone health.
GHK-Cu osteoblast activation published. CJC/Ipam IGF-1 bone density data. GLOW stack mechanism validated.
FDA-approved melanocortin receptor agonism for sexual dysfunction â acting centrally on desire via CNS receptors rather than peripherally on blood flow. Effective across sexes.
PT-141 (Vyleesi) FDA approved 2019. Phase III clinical trials published NEJM.